Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: REGN2810 Clear all
Completed Phase 1 Interventional

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

NCT03005782
View directory record Official record
Conditions
Malignancies
Interventions
REGN3767, cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
33
States / cities
Encinitas, California • Fresno, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 1 Interventional

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

NCT03017820
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

NCT06205836
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cemiplimab, Fianlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Terminated Phase 1 Interventional

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

NCT04465487
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
REGN6569, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 20, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

NCT04154943
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

NCT06731270
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Cemiplimab, Computed Tomography, Diclofenac Potassium, Electronic Health Record Review, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Positron Emission Tomography
Biological · Procedure · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

NCT04177810
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Cemiplimab, Plerixafor
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417
View directory record Official record
Conditions
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Irvine, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

NCT06469281
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions
27T51, Cemiplimab, Bevacizumab
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

NCT07147231
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Pidnarulex, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Terminated Phase 1 Interventional

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

NCT04729725
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 20, 2026, 12:41 AM EDT
Terminated Phase 1 Interventional

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03580694
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
REGN4659, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

NCT07050186
View directory record Official record
Conditions
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Digital Photography, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Suspended Phase 3 Interventional

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

NCT06568172
View directory record Official record
Conditions
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
196
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Goodyear, Arizona • Duarte, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

NCT03916627
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
cemiplimab, Platinum Doublet, fianlimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Withdrawn Phase 2 Interventional

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

NCT06943664
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery
Procedure · Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869
View directory record Official record
Conditions
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
Interventions
cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

NCT06623656
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Active, not recruiting Phase 2 Interventional

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

NCT04315701
View directory record Official record
Conditions
Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer, Stage III Skin Cancer
Interventions
Cemiplimab, Resection
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Recruiting Phase 2 Interventional

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 12:41 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119
View directory record Official record
Conditions
Glioblastoma
Interventions
Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 20, 2026, 12:41 AM EDT